Ovid Therapeutics Inc. - Common Stock par value $0.001 per share (OVID)

Historical Holders from Q2 2017 to Q3 2025

Symbol
OVID on Nasdaq
Type / Class
Equity / Common Stock par value $0.001 per share
Shares outstanding
134M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
36.2M
Holdings value
$47.1M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
80
Number of buys
42
Number of sells
-36
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ovid Therapeutics Inc. - Common Stock par value $0.001 per share (OVID)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 9.9% $19.9M 13.3M RA Capital Management, L.P. 11 Dec 2025
Affinity Asset Advisors, LLC 9% $18.2M 12.1M Affinity Asset Advisors, LLC 11 Dec 2025
TAKEDA PHARMACEUTICAL CO LTD 12.3% $11.7M 8.78M Takeda Pharmaceutical Company Limited 08 Dec 2025
JANUS HENDERSON GROUP PLC 9.99% $9.46M 7.11M JANUS HENDERSON GROUP PLC 28 Nov 2025
Madison Avenue Partners, LP 4% $970K 2.85M Madison Avenue Partners, LP 31 Dec 2024
BlackRock, Inc. 1.9% $452K 1.37M BlackRock, Inc. 30 Jun 2025
Rubric Capital Management LP 0.67% $153K 479K Rubric Capital Management LP 30 Jun 2025

Institutional Holders of Ovid Therapeutics Inc. - Common Stock par value $0.001 per share (OVID)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 36.2M $47.1M +$6.61M $1.30 80
2025 Q2 36M $11.9M -$3.39M $0.33 69
2025 Q1 46.4M $14.5M -$2.82M $0.31 81
2024 Q4 47.6M $44.4M +$934K $0.93 80
2024 Q3 46.3M $54.7M -$2.31M $1.18 75
2024 Q2 46M $35.4M -$20.9M $0.77 72
2024 Q1 50.1M $153M -$4.73M $3.05 80
2023 Q4 51.7M $166M +$8.16M $3.22 77
2023 Q3 42.3M $163M +$5.68M $3.84 64
2023 Q2 41M $135M +$8.71M $3.28 69
2023 Q1 38.7M $99.8M +$651K $2.58 60
2022 Q4 38.6M $71.7M +$2.58M $1.86 58
2022 Q3 35.6M $65.5M +$1.72M $1.84 55
2022 Q2 34.6M $74.5M -$3.01M $2.15 52
2022 Q1 35.1M $110M +$3.43M $3.14 61
2021 Q4 34M $109M +$1.24M $3.21 65
2021 Q3 33.6M $113M -$90.8K $3.36 70
2021 Q2 33.4M $130M -$11M $3.91 76
2021 Q1 36.3M $146M +$42.6M $4.02 85
2020 Q4 27.4M $63.3M -$6.38M $2.31 75
2020 Q3 25.1M $144M +$11.1M $5.74 90
2020 Q2 21.8M $161M +$48.5M $7.37 78
2020 Q1 15.9M $47.3M -$7.21M $2.98 56
2019 Q4 17.8M $73.7M +$38.3M $4.15 58
2019 Q3 8.21M $26.6M -$5.12M $3.24 37
2019 Q2 10.1M $18.7M -$3.71M $1.85 33
2019 Q1 12.3M $21.7M +$9.09M $1.77 47
2018 Q4 6.84M $16.5M -$8.21M $2.42 46
2018 Q3 7.39M $41.9M -$3.04M $5.67 49
2018 Q2 7.65M $59.7M +$4.81M $7.80 47
2018 Q1 7.05M $49.8M -$9.28M $7.07 48
2017 Q4 7.82M $77.2M +$5.98M $9.87 49
2017 Q3 7.22M $61.5M -$7.07M $8.57 42
2017 Q2 7.99M $81.8M +$81.8M $10.49 43